The	O
correlation	O
between	O
CYP2D6	B:C0057223
isoenzyme	O
activity	I:C0243102
and	O
haloperidol	O
efficacy	O
and	O
safety	O
profile	O
in	O
patients	O
with	O
alcohol	O
addiction	I:C0001973
during	O
the	O
exacerbation	O
of	O
the	O
addiction	O
Today	O
,	O
it	O
is	O
proved	O
that	O
isoenzymes	O
CYP2D6	O
and	O
CYP3A4	O
are	O
involved	O
in	O
metabolism	O
of	O
haloperidol	O
.	O

The	O
correlation	O
between	O
CYP2D6	O
isoenzyme	B:C0243102
activity	I:C0243102
and	O
haloperidol	O
efficacy	O
and	O
safety	O
profile	O
in	O
patients	O
with	O
alcohol	O
addiction	I:C0001973
during	O
the	O
exacerbation	O
of	O
the	O
addiction	O
Today	O
,	O
it	O
is	O
proved	O
that	O
isoenzymes	O
CYP2D6	O
and	O
CYP3A4	O
are	O
involved	O
in	O
metabolism	O
of	O
haloperidol	O
.	O

The	O
correlation	O
between	O
CYP2D6	O
isoenzyme	O
activity	I:C0243102
and	O
haloperidol	B:C0018546
efficacy	O
and	O
safety	O
profile	O
in	O
patients	O
with	O
alcohol	O
addiction	I:C0001973
during	O
the	O
exacerbation	O
of	O
the	O
addiction	O
Today	O
,	O
it	O
is	O
proved	O
that	O
isoenzymes	O
CYP2D6	O
and	O
CYP3A4	O
are	O
involved	O
in	O
metabolism	O
of	O
haloperidol	O
.	O

The	O
correlation	O
between	O
CYP2D6	O
isoenzyme	O
activity	I:C0243102
and	O
haloperidol	O
efficacy	O
and	O
safety	O
profile	O
in	O
patients	O
with	O
alcohol	B:C0001973
addiction	I:C0001973
during	O
the	O
exacerbation	O
of	O
the	O
addiction	O
Today	O
,	O
it	O
is	O
proved	O
that	O
isoenzymes	O
CYP2D6	O
and	O
CYP3A4	O
are	O
involved	O
in	O
metabolism	O
of	O
haloperidol	O
.	O

The	O
correlation	O
between	O
CYP2D6	O
isoenzyme	O
activity	I:C0243102
and	O
haloperidol	O
efficacy	O
and	O
safety	O
profile	O
in	O
patients	O
with	O
alcohol	O
addiction	I:C0001973
during	O
the	O
exacerbation	B:C4086268
of	O
the	O
addiction	O
Today	O
,	O
it	O
is	O
proved	O
that	O
isoenzymes	O
CYP2D6	O
and	O
CYP3A4	O
are	O
involved	O
in	O
metabolism	O
of	O
haloperidol	O
.	O

The	O
correlation	O
between	O
CYP2D6	O
isoenzyme	O
activity	I:C0243102
and	O
haloperidol	O
efficacy	O
and	O
safety	O
profile	O
in	O
patients	O
with	O
alcohol	O
addiction	I:C0001973
during	O
the	O
exacerbation	O
of	O
the	O
addiction	B:C0001973
Today	O
,	O
it	O
is	O
proved	O
that	O
isoenzymes	O
CYP2D6	O
and	O
CYP3A4	O
are	O
involved	O
in	O
metabolism	O
of	O
haloperidol	O
.	O

The	O
correlation	O
between	O
CYP2D6	O
isoenzyme	O
activity	I:C0243102
and	O
haloperidol	O
efficacy	O
and	O
safety	O
profile	O
in	O
patients	O
with	O
alcohol	O
addiction	I:C0001973
during	O
the	O
exacerbation	O
of	O
the	O
addiction	O
Today	O
,	O
it	O
is	O
proved	O
that	O
isoenzymes	B:C0022173
CYP2D6	O
and	O
CYP3A4	O
are	O
involved	O
in	O
metabolism	O
of	O
haloperidol	O
.	O

The	O
correlation	O
between	O
CYP2D6	O
isoenzyme	O
activity	I:C0243102
and	O
haloperidol	O
efficacy	O
and	O
safety	O
profile	O
in	O
patients	O
with	O
alcohol	O
addiction	I:C0001973
during	O
the	O
exacerbation	O
of	O
the	O
addiction	O
Today	O
,	O
it	O
is	O
proved	O
that	O
isoenzymes	O
CYP2D6	B:C0057223
and	O
CYP3A4	O
are	O
involved	O
in	O
metabolism	O
of	O
haloperidol	O
.	O

The	O
correlation	O
between	O
CYP2D6	O
isoenzyme	O
activity	I:C0243102
and	O
haloperidol	O
efficacy	O
and	O
safety	O
profile	O
in	O
patients	O
with	O
alcohol	O
addiction	I:C0001973
during	O
the	O
exacerbation	O
of	O
the	O
addiction	O
Today	O
,	O
it	O
is	O
proved	O
that	O
isoenzymes	O
CYP2D6	O
and	O
CYP3A4	B:C1142644
are	O
involved	O
in	O
metabolism	O
of	O
haloperidol	O
.	O

The	O
correlation	O
between	O
CYP2D6	O
isoenzyme	O
activity	I:C0243102
and	O
haloperidol	O
efficacy	O
and	O
safety	O
profile	O
in	O
patients	O
with	O
alcohol	O
addiction	I:C0001973
during	O
the	O
exacerbation	O
of	O
the	O
addiction	O
Today	O
,	O
it	O
is	O
proved	O
that	O
isoenzymes	O
CYP2D6	O
and	O
CYP3A4	O
are	O
involved	O
in	O
metabolism	B:C0025519
of	O
haloperidol	O
.	O

The	O
correlation	O
between	O
CYP2D6	O
isoenzyme	O
activity	I:C0243102
and	O
haloperidol	O
efficacy	O
and	O
safety	O
profile	O
in	O
patients	O
with	O
alcohol	O
addiction	I:C0001973
during	O
the	O
exacerbation	O
of	O
the	O
addiction	O
Today	O
,	O
it	O
is	O
proved	O
that	O
isoenzymes	O
CYP2D6	O
and	O
CYP3A4	O
are	O
involved	O
in	O
metabolism	O
of	O
haloperidol	B:C0018546
.	O

In	O
our	O
previous	O
investigation	O
,	O
we	O
found	O
a	O
medium	O
correlation	O
between	O
the	O
efficacy	O
and	O
safety	O
of	O
haloperidol	B:C0018546
and	O
the	O
activity	O
of	O
CYP3A4	O
in	O
patients	O
with	O
alcohol	O
abuse	I:C0085762
.	O

In	O
our	O
previous	O
investigation	O
,	O
we	O
found	O
a	O
medium	O
correlation	O
between	O
the	O
efficacy	O
and	O
safety	O
of	O
haloperidol	O
and	O
the	O
activity	B:C0243102
of	O
CYP3A4	O
in	O
patients	O
with	O
alcohol	O
abuse	I:C0085762
.	O

In	O
our	O
previous	O
investigation	O
,	O
we	O
found	O
a	O
medium	O
correlation	O
between	O
the	O
efficacy	O
and	O
safety	O
of	O
haloperidol	O
and	O
the	O
activity	O
of	O
CYP3A4	B:C1142644
in	O
patients	O
with	O
alcohol	O
abuse	I:C0085762
.	O

In	O
our	O
previous	O
investigation	O
,	O
we	O
found	O
a	O
medium	O
correlation	O
between	O
the	O
efficacy	O
and	O
safety	O
of	O
haloperidol	O
and	O
the	O
activity	O
of	O
CYP3A4	O
in	O
patients	O
with	O
alcohol	B:C0085762
abuse	I:C0085762
.	O

The	O
aim	O
of	O
this	O
study	B:C2603343
was	O
to	O
evaluate	O
the	O
correlation	O
between	O
the	O
activity	O
of	O
CYP2D6	O
and	O
the	O
efficacy	O
and	O
safety	O
of	O
haloperidol	O
in	O
patients	O
with	O
diagnosed	O
alcohol	O
abuse	I:C0085762
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
correlation	O
between	O
the	O
activity	B:C0243102
of	O
CYP2D6	O
and	O
the	O
efficacy	O
and	O
safety	O
of	O
haloperidol	O
in	O
patients	O
with	O
diagnosed	O
alcohol	O
abuse	I:C0085762
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
correlation	O
between	O
the	O
activity	O
of	O
CYP2D6	B:C0057223
and	O
the	O
efficacy	O
and	O
safety	O
of	O
haloperidol	O
in	O
patients	O
with	O
diagnosed	O
alcohol	O
abuse	I:C0085762
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
correlation	O
between	O
the	O
activity	O
of	O
CYP2D6	O
and	O
the	O
efficacy	O
and	O
safety	O
of	O
haloperidol	B:C0018546
in	O
patients	O
with	O
diagnosed	O
alcohol	O
abuse	I:C0085762
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
correlation	O
between	O
the	O
activity	O
of	O
CYP2D6	O
and	O
the	O
efficacy	O
and	O
safety	O
of	O
haloperidol	O
in	O
patients	O
with	O
diagnosed	O
alcohol	B:C0085762
abuse	I:C0085762
.	O

The	O
study	B:C2603343
involved	O
70	O
men	O
(	O
average	O
age	O
:	O
40.83±9.92	O
years	O
)	O
with	O
alcohol	O
addiction	I:C0001973
.	O

The	O
study	O
involved	O
70	O
men	B:C0025266
(	O
average	O
age	O
:	O
40.83±9.92	O
years	O
)	O
with	O
alcohol	O
addiction	I:C0001973
.	O

The	O
study	O
involved	O
70	O
men	O
(	O
average	O
age	O
:	O
40.83±9.92	O
years	O
)	O
with	O
alcohol	B:C0001973
addiction	I:C0001973
.	O

A	O
series	O
of	O
psychometric	B:C0349674
scales	I:C0349674
were	O
used	O
in	O
the	O
research	O
.	O

A	O
series	O
of	O
psychometric	O
scales	I:C0349674
were	O
used	O
in	O
the	O
research	B:C0035168
.	O

The	O
activity	B:C0243102
of	O
CYP2D6	O
was	O
evaluated	O
by	O
high	O
-	I:C0008562
performance	I:C0008562
liquid	I:C0008562
chromatography	I:C0008562
with	O
mass	O
spectrometry	I:C0037813
using	O
the	O
ratio	O
of	O
6	O
-	I:C0049585
hydroxy	I:C0049585
-	I:C0049585
1,2,3,4-	I:C0049585
tetrahydro-beta	I:C0049585
-	I:C0049585
carboline	I:C0049585
to	O
pinoline	O
.	O

The	O
activity	O
of	O
CYP2D6	B:C0057223
was	O
evaluated	O
by	O
high	O
-	I:C0008562
performance	I:C0008562
liquid	I:C0008562
chromatography	I:C0008562
with	O
mass	O
spectrometry	I:C0037813
using	O
the	O
ratio	O
of	O
6	O
-	I:C0049585
hydroxy	I:C0049585
-	I:C0049585
1,2,3,4-	I:C0049585
tetrahydro-beta	I:C0049585
-	I:C0049585
carboline	I:C0049585
to	O
pinoline	O
.	O

The	O
activity	O
of	O
CYP2D6	O
was	O
evaluated	O
by	O
high	B:C0008562
-	I:C0008562
performance	I:C0008562
liquid	I:C0008562
chromatography	I:C0008562
with	O
mass	O
spectrometry	I:C0037813
using	O
the	O
ratio	O
of	O
6	O
-	I:C0049585
hydroxy	I:C0049585
-	I:C0049585
1,2,3,4-	I:C0049585
tetrahydro-beta	I:C0049585
-	I:C0049585
carboline	I:C0049585
to	O
pinoline	O
.	O

The	O
activity	O
of	O
CYP2D6	O
was	O
evaluated	O
by	O
high	O
-	I:C0008562
performance	I:C0008562
liquid	I:C0008562
chromatography	I:C0008562
with	O
mass	B:C0037813
spectrometry	I:C0037813
using	O
the	O
ratio	O
of	O
6	O
-	I:C0049585
hydroxy	I:C0049585
-	I:C0049585
1,2,3,4-	I:C0049585
tetrahydro-beta	I:C0049585
-	I:C0049585
carboline	I:C0049585
to	O
pinoline	O
.	O

The	O
activity	O
of	O
CYP2D6	O
was	O
evaluated	O
by	O
high	O
-	I:C0008562
performance	I:C0008562
liquid	I:C0008562
chromatography	I:C0008562
with	O
mass	O
spectrometry	I:C0037813
using	O
the	O
ratio	O
of	O
6	B:C0049585
-	I:C0049585
hydroxy	I:C0049585
-	I:C0049585
1,2,3,4-	I:C0049585
tetrahydro-beta	I:C0049585
-	I:C0049585
carboline	I:C0049585
to	O
pinoline	O
.	O

The	O
activity	O
of	O
CYP2D6	O
was	O
evaluated	O
by	O
high	O
-	I:C0008562
performance	I:C0008562
liquid	I:C0008562
chromatography	I:C0008562
with	O
mass	O
spectrometry	I:C0037813
using	O
the	O
ratio	O
of	O
6	O
-	I:C0049585
hydroxy	I:C0049585
-	I:C0049585
1,2,3,4-	I:C0049585
tetrahydro-beta	I:C0049585
-	I:C0049585
carboline	I:C0049585
to	O
pinoline	B:C0049646
.	O

Genotyping	B:C1285573
of	O
CYP2D6	O
(	O
1846	O
G	O
>	O
A	O
)	O
was	O
performed	O
using	O
real	O
-	I:C1709846
time	I:C1709846
polymerase	I:C1709846
chain	I:C1709846
reaction	I:C1709846
.	O

Genotyping	O
of	O
CYP2D6	B:C0057223
(	O
1846	O
G	O
>	O
A	O
)	O
was	O
performed	O
using	O
real	O
-	I:C1709846
time	I:C1709846
polymerase	I:C1709846
chain	I:C1709846
reaction	I:C1709846
.	O

Genotyping	O
of	O
CYP2D6	O
(	O
1846	O
G	O
>	O
A	O
)	O
was	O
performed	O
using	O
real	B:C1709846
-	I:C1709846
time	I:C1709846
polymerase	I:C1709846
chain	I:C1709846
reaction	I:C1709846
.	O

According	O
to	O
results	O
of	O
correlation	B:C0010101
analysis	I:C0010101
,	O
statistically	O
significant	O
values	O
of	O
Spearman	O
correlation	O
coefficient	O
(	O
rs	O
)	O
between	O
the	O
activity	O
of	O
CYP2D6	O
and	O
the	O
difference	O
of	O
points	O
in	O
psychometric	O
scale	I:C0349674
were	O
obtained	O
in	O
patients	O
receiving	O
haloperidol	O
in	O
injection	O
form	I:C1272883
(	O
Sheehan	O
Clinical	O
Anxiety	O
Rating	O
Scale	O
=-	O
0.721	O
[	O
P	O
<	O
0.001	O
]	O
and	O
Udvald	O
for	O
Kliniske	O
Undersogelser	O
Side	O
Effect	O
Rating	O
Scale	O
=	O
0.692	O
[	O
P	O
<	O
0.001	O
]	O
)	O
and	O
in	O
those	O
receiving	O
haloperidol	O
in	O
tablet	O
form	I:C0993159
(	O
Covi	O
Anxiety	I:C0451073
Scale	I:C0451073
=-	O
0.851	O
[	O
P	O
<	O
0.001	O
]	O
and	O
Udvald	O
for	O
Kliniske	O
Undersogelser	O
Side	O
Effect	O
Rating	O
Scale	O
=	O
0.797	O
[	O
P	O
<	O
0.001	O
]	O
)	O
.	O

According	O
to	O
results	O
of	O
correlation	O
analysis	I:C0010101
,	O
statistically	O
significant	O
values	O
of	O
Spearman	O
correlation	O
coefficient	O
(	O
rs	O
)	O
between	O
the	O
activity	B:C0243102
of	O
CYP2D6	O
and	O
the	O
difference	O
of	O
points	O
in	O
psychometric	O
scale	I:C0349674
were	O
obtained	O
in	O
patients	O
receiving	O
haloperidol	O
in	O
injection	O
form	I:C1272883
(	O
Sheehan	O
Clinical	O
Anxiety	O
Rating	O
Scale	O
=-	O
0.721	O
[	O
P	O
<	O
0.001	O
]	O
and	O
Udvald	O
for	O
Kliniske	O
Undersogelser	O
Side	O
Effect	O
Rating	O
Scale	O
=	O
0.692	O
[	O
P	O
<	O
0.001	O
]	O
)	O
and	O
in	O
those	O
receiving	O
haloperidol	O
in	O
tablet	O
form	I:C0993159
(	O
Covi	O
Anxiety	I:C0451073
Scale	I:C0451073
=-	O
0.851	O
[	O
P	O
<	O
0.001	O
]	O
and	O
Udvald	O
for	O
Kliniske	O
Undersogelser	O
Side	O
Effect	O
Rating	O
Scale	O
=	O
0.797	O
[	O
P	O
<	O
0.001	O
]	O
)	O
.	O

According	O
to	O
results	O
of	O
correlation	O
analysis	I:C0010101
,	O
statistically	O
significant	O
values	O
of	O
Spearman	O
correlation	O
coefficient	O
(	O
rs	O
)	O
between	O
the	O
activity	O
of	O
CYP2D6	B:C0057223
and	O
the	O
difference	O
of	O
points	O
in	O
psychometric	O
scale	I:C0349674
were	O
obtained	O
in	O
patients	O
receiving	O
haloperidol	O
in	O
injection	O
form	I:C1272883
(	O
Sheehan	O
Clinical	O
Anxiety	O
Rating	O
Scale	O
=-	O
0.721	O
[	O
P	O
<	O
0.001	O
]	O
and	O
Udvald	O
for	O
Kliniske	O
Undersogelser	O
Side	O
Effect	O
Rating	O
Scale	O
=	O
0.692	O
[	O
P	O
<	O
0.001	O
]	O
)	O
and	O
in	O
those	O
receiving	O
haloperidol	O
in	O
tablet	O
form	I:C0993159
(	O
Covi	O
Anxiety	I:C0451073
Scale	I:C0451073
=-	O
0.851	O
[	O
P	O
<	O
0.001	O
]	O
and	O
Udvald	O
for	O
Kliniske	O
Undersogelser	O
Side	O
Effect	O
Rating	O
Scale	O
=	O
0.797	O
[	O
P	O
<	O
0.001	O
]	O
)	O
.	O

According	O
to	O
results	O
of	O
correlation	O
analysis	I:C0010101
,	O
statistically	O
significant	O
values	O
of	O
Spearman	O
correlation	O
coefficient	O
(	O
rs	O
)	O
between	O
the	O
activity	O
of	O
CYP2D6	O
and	O
the	O
difference	O
of	O
points	O
in	O
psychometric	B:C0349674
scale	I:C0349674
were	O
obtained	O
in	O
patients	O
receiving	O
haloperidol	O
in	O
injection	O
form	I:C1272883
(	O
Sheehan	O
Clinical	O
Anxiety	O
Rating	O
Scale	O
=-	O
0.721	O
[	O
P	O
<	O
0.001	O
]	O
and	O
Udvald	O
for	O
Kliniske	O
Undersogelser	O
Side	O
Effect	O
Rating	O
Scale	O
=	O
0.692	O
[	O
P	O
<	O
0.001	O
]	O
)	O
and	O
in	O
those	O
receiving	O
haloperidol	O
in	O
tablet	O
form	I:C0993159
(	O
Covi	O
Anxiety	I:C0451073
Scale	I:C0451073
=-	O
0.851	O
[	O
P	O
<	O
0.001	O
]	O
and	O
Udvald	O
for	O
Kliniske	O
Undersogelser	O
Side	O
Effect	O
Rating	O
Scale	O
=	O
0.797	O
[	O
P	O
<	O
0.001	O
]	O
)	O
.	O

According	O
to	O
results	O
of	O
correlation	O
analysis	I:C0010101
,	O
statistically	O
significant	O
values	O
of	O
Spearman	O
correlation	O
coefficient	O
(	O
rs	O
)	O
between	O
the	O
activity	O
of	O
CYP2D6	O
and	O
the	O
difference	O
of	O
points	O
in	O
psychometric	O
scale	I:C0349674
were	O
obtained	O
in	O
patients	O
receiving	O
haloperidol	B:C0018546
in	O
injection	O
form	I:C1272883
(	O
Sheehan	O
Clinical	O
Anxiety	O
Rating	O
Scale	O
=-	O
0.721	O
[	O
P	O
<	O
0.001	O
]	O
and	O
Udvald	O
for	O
Kliniske	O
Undersogelser	O
Side	O
Effect	O
Rating	O
Scale	O
=	O
0.692	O
[	O
P	O
<	O
0.001	O
]	O
)	O
and	O
in	O
those	O
receiving	O
haloperidol	O
in	O
tablet	O
form	I:C0993159
(	O
Covi	O
Anxiety	I:C0451073
Scale	I:C0451073
=-	O
0.851	O
[	O
P	O
<	O
0.001	O
]	O
and	O
Udvald	O
for	O
Kliniske	O
Undersogelser	O
Side	O
Effect	O
Rating	O
Scale	O
=	O
0.797	O
[	O
P	O
<	O
0.001	O
]	O
)	O
.	O

According	O
to	O
results	O
of	O
correlation	O
analysis	I:C0010101
,	O
statistically	O
significant	O
values	O
of	O
Spearman	O
correlation	O
coefficient	O
(	O
rs	O
)	O
between	O
the	O
activity	O
of	O
CYP2D6	O
and	O
the	O
difference	O
of	O
points	O
in	O
psychometric	O
scale	I:C0349674
were	O
obtained	O
in	O
patients	O
receiving	O
haloperidol	O
in	O
injection	B:C1272883
form	I:C1272883
(	O
Sheehan	O
Clinical	O
Anxiety	O
Rating	O
Scale	O
=-	O
0.721	O
[	O
P	O
<	O
0.001	O
]	O
and	O
Udvald	O
for	O
Kliniske	O
Undersogelser	O
Side	O
Effect	O
Rating	O
Scale	O
=	O
0.692	O
[	O
P	O
<	O
0.001	O
]	O
)	O
and	O
in	O
those	O
receiving	O
haloperidol	O
in	O
tablet	O
form	I:C0993159
(	O
Covi	O
Anxiety	I:C0451073
Scale	I:C0451073
=-	O
0.851	O
[	O
P	O
<	O
0.001	O
]	O
and	O
Udvald	O
for	O
Kliniske	O
Undersogelser	O
Side	O
Effect	O
Rating	O
Scale	O
=	O
0.797	O
[	O
P	O
<	O
0.001	O
]	O
)	O
.	O

According	O
to	O
results	O
of	O
correlation	O
analysis	I:C0010101
,	O
statistically	O
significant	O
values	O
of	O
Spearman	O
correlation	O
coefficient	O
(	O
rs	O
)	O
between	O
the	O
activity	O
of	O
CYP2D6	O
and	O
the	O
difference	O
of	O
points	O
in	O
psychometric	O
scale	I:C0349674
were	O
obtained	O
in	O
patients	O
receiving	O
haloperidol	O
in	O
injection	O
form	I:C1272883
(	O
Sheehan	O
Clinical	O
Anxiety	O
Rating	O
Scale	O
=-	O
0.721	O
[	O
P	O
<	O
0.001	O
]	O
and	O
Udvald	O
for	O
Kliniske	O
Undersogelser	O
Side	O
Effect	O
Rating	O
Scale	O
=	O
0.692	O
[	O
P	O
<	O
0.001	O
]	O
)	O
and	O
in	O
those	O
receiving	O
haloperidol	B:C0018546
in	O
tablet	O
form	I:C0993159
(	O
Covi	O
Anxiety	I:C0451073
Scale	I:C0451073
=-	O
0.851	O
[	O
P	O
<	O
0.001	O
]	O
and	O
Udvald	O
for	O
Kliniske	O
Undersogelser	O
Side	O
Effect	O
Rating	O
Scale	O
=	O
0.797	O
[	O
P	O
<	O
0.001	O
]	O
)	O
.	O

According	O
to	O
results	O
of	O
correlation	O
analysis	I:C0010101
,	O
statistically	O
significant	O
values	O
of	O
Spearman	O
correlation	O
coefficient	O
(	O
rs	O
)	O
between	O
the	O
activity	O
of	O
CYP2D6	O
and	O
the	O
difference	O
of	O
points	O
in	O
psychometric	O
scale	I:C0349674
were	O
obtained	O
in	O
patients	O
receiving	O
haloperidol	O
in	O
injection	O
form	I:C1272883
(	O
Sheehan	O
Clinical	O
Anxiety	O
Rating	O
Scale	O
=-	O
0.721	O
[	O
P	O
<	O
0.001	O
]	O
and	O
Udvald	O
for	O
Kliniske	O
Undersogelser	O
Side	O
Effect	O
Rating	O
Scale	O
=	O
0.692	O
[	O
P	O
<	O
0.001	O
]	O
)	O
and	O
in	O
those	O
receiving	O
haloperidol	O
in	O
tablet	B:C0993159
form	I:C0993159
(	O
Covi	O
Anxiety	I:C0451073
Scale	I:C0451073
=-	O
0.851	O
[	O
P	O
<	O
0.001	O
]	O
and	O
Udvald	O
for	O
Kliniske	O
Undersogelser	O
Side	O
Effect	O
Rating	O
Scale	O
=	O
0.797	O
[	O
P	O
<	O
0.001	O
]	O
)	O
.	O

According	O
to	O
results	O
of	O
correlation	O
analysis	I:C0010101
,	O
statistically	O
significant	O
values	O
of	O
Spearman	O
correlation	O
coefficient	O
(	O
rs	O
)	O
between	O
the	O
activity	O
of	O
CYP2D6	O
and	O
the	O
difference	O
of	O
points	O
in	O
psychometric	O
scale	I:C0349674
were	O
obtained	O
in	O
patients	O
receiving	O
haloperidol	O
in	O
injection	O
form	I:C1272883
(	O
Sheehan	O
Clinical	O
Anxiety	O
Rating	O
Scale	O
=-	O
0.721	O
[	O
P	O
<	O
0.001	O
]	O
and	O
Udvald	O
for	O
Kliniske	O
Undersogelser	O
Side	O
Effect	O
Rating	O
Scale	O
=	O
0.692	O
[	O
P	O
<	O
0.001	O
]	O
)	O
and	O
in	O
those	O
receiving	O
haloperidol	O
in	O
tablet	O
form	I:C0993159
(	O
Covi	B:C0451073
Anxiety	I:C0451073
Scale	I:C0451073
=-	O
0.851	O
[	O
P	O
<	O
0.001	O
]	O
and	O
Udvald	O
for	O
Kliniske	O
Undersogelser	O
Side	O
Effect	O
Rating	O
Scale	O
=	O
0.797	O
[	O
P	O
<	O
0.001	O
]	O
)	O
.	O

This	O
study	B:C2603343
demonstrated	O
the	O
correlations	O
between	O
the	O
activity	O
of	O
CYP2D6	O
isozyme	I:C0057223
and	O
the	O
efficacy	O
and	O
safety	O
of	O
haloperidol	O
in	O
patients	O
with	O
alcohol	O
addiction	I:C0001973
.	O

This	O
study	O
demonstrated	O
the	O
correlations	O
between	O
the	O
activity	B:C0243102
of	O
CYP2D6	O
isozyme	I:C0057223
and	O
the	O
efficacy	O
and	O
safety	O
of	O
haloperidol	O
in	O
patients	O
with	O
alcohol	O
addiction	I:C0001973
.	O

This	O
study	O
demonstrated	O
the	O
correlations	O
between	O
the	O
activity	O
of	O
CYP2D6	B:C0057223
isozyme	I:C0057223
and	O
the	O
efficacy	O
and	O
safety	O
of	O
haloperidol	O
in	O
patients	O
with	O
alcohol	O
addiction	I:C0001973
.	O

This	O
study	O
demonstrated	O
the	O
correlations	O
between	O
the	O
activity	O
of	O
CYP2D6	O
isozyme	I:C0057223
and	O
the	O
efficacy	O
and	O
safety	O
of	O
haloperidol	B:C0018546
in	O
patients	O
with	O
alcohol	O
addiction	I:C0001973
.	O

This	O
study	O
demonstrated	O
the	O
correlations	O
between	O
the	O
activity	O
of	O
CYP2D6	O
isozyme	I:C0057223
and	O
the	O
efficacy	O
and	O
safety	O
of	O
haloperidol	O
in	O
patients	O
with	O
alcohol	B:C0001973
addiction	I:C0001973
.	O

